Emyria Ltd (EMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Emyria Ltd (EMD) has a cash flow conversion efficiency ratio of -0.316x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.67 Million ≈ $-1.18 Million USD) by net assets (AU$5.31 Million ≈ $3.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check asset allocation strategy of Emyria Ltd to assess the company's strategic physical and investment asset allocation.
Emyria Ltd - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Emyria Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Emyria Ltd net assets for net asset value and shareholders' equity analysis.
Emyria Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Emyria Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Femasys Inc
NASDAQ:FEMY
|
-0.706x |
|
Sunrise New Energy Co. Ltd
NASDAQ:EPOW
|
-0.678x |
|
Honey Badger Silver Inc
V:TUF
|
-0.508x |
|
Skin n Skin Co. Ltd
KQ:159910
|
-0.211x |
|
Despec Bilgisayar Pazarlama ve Ticaret AS
IS:DESPC
|
-1.667x |
|
Saga Furs Oyj C
HE:SAGCV
|
-0.248x |
|
Bull Will Co Ltd
TWO:6259
|
0.031x |
|
Teaminvest Private Group Ltd
AU:TIP
|
0.063x |
Annual Cash Flow Conversion Efficiency for Emyria Ltd (2018–2025)
The table below shows the annual cash flow conversion efficiency of Emyria Ltd from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see EMD stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.31 Million ≈ $3.75 Million |
AU$-2.70 Million ≈ $-1.91 Million |
-0.510x | +71.14% |
| 2024-06-30 | AU$2.43 Million ≈ $1.72 Million |
AU$-4.28 Million ≈ $-3.03 Million |
-1.767x | -218.22% |
| 2023-06-30 | AU$6.79 Million ≈ $4.81 Million |
AU$-3.77 Million ≈ $-2.67 Million |
-0.555x | +35.34% |
| 2022-06-30 | AU$6.32 Million ≈ $4.47 Million |
AU$-5.43 Million ≈ $-3.84 Million |
-0.859x | -56.53% |
| 2021-06-30 | AU$7.18 Million ≈ $5.08 Million |
AU$-3.94 Million ≈ $-2.79 Million |
-0.549x | +53.40% |
| 2020-06-30 | AU$3.78 Million ≈ $2.68 Million |
AU$-4.45 Million ≈ $-3.15 Million |
-1.177x | +77.33% |
| 2019-06-30 | AU$499.54K ≈ $353.46K |
AU$-2.59 Million ≈ $-1.83 Million |
-5.191x | -69937.67% |
| 2018-06-30 | AU$2.81 Million ≈ $1.99 Million |
AU$-20.82K ≈ $-14.73K |
-0.007x | -- |
About Emyria Ltd
Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-… Read more